$FENC
FENNEC PHARMACEUTICALS INC. Stock $fenc

$fenc Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000114420418043914 Filed on August 13, 2018

Income Statement

Concept	2018 Q2	2017 Q2	2017 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.870M	$1.150M	$550.0K
YoY Change	62.61%	101.75%	34.15%
% of Gross Profit
Research & Development	$798.0K	$333.0K	$230.0K
YoY Change	139.64%	139.57%	389.36%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$798.0K	$333.0K	$770.0K
YoY Change	139.64%	139.57%	1538.3%
Operating Profit	-$2.665M	-$1.479M
YoY Change	80.19%	109.19%
Interest Expense	$70.00K	-$120.0K	-$30.00K
YoY Change	-158.33%	1100.0%	-200.0%
% of Operating Profit
Other Income/Expense, Net	$78.00K	-$119.0K	-$1.000K
YoY Change	-165.55%	600.0%	-102.94%
Pretax Income	-$2.590M	-$1.600M	-$810.0K
YoY Change	61.88%	122.22%	92.86%
Income Tax
% Of Pretax Income
Net Earnings	-$2.587M	-$1.598M	-$806.0K
YoY Change	61.89%	120.72%	91.9%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.14	-$0.11	-$0.06
Diluted Earnings Per Share	-$0.14	-$0.11	-$0.06
COMMON SHARES
Basic Shares Outstanding	18.59M shares	14.19M shares	13.64M shares
Diluted Shares Outstanding	18.59M shares	14.19M shares

Balance Sheet

Concept	2018 Q2	2017 Q2	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$25.64M	$10.23M	$3.250M
YoY Change	150.64%	101.38%	490.91%
Cash & Equivalents	$25.64M	$10.23M	$3.251M
Short-Term Investments
Other Short-Term Assets	$4.000K	$30.00K	$40.00K
YoY Change	-86.67%	0.0%	0.0%
Inventory
Prepaid Expenses	$60.00K
Receivables
Other Receivables
Total Short-Term Assets	$25.70M	$10.26M	$3.290M
YoY Change	150.49%	101.18%	457.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$4.000K	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$25.70M	$10.26M	$3.290M
Total Long-Term Assets	$4.000K	$0.00	$0.00
Total Assets	$25.70M	$10.26M	$3.290M
YoY Change	150.53%	101.18%	457.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$709.0K	$300.0K	$220.0K
YoY Change	136.33%	-14.29%	-4.35%
Accrued Expenses	$138.0K	$90.00K	$130.0K
YoY Change	53.33%	80.0%	62.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$847.0K	$580.0K	$430.0K
YoY Change	46.03%	28.89%	22.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$847.0K	$580.0K	$430.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$847.0K	$580.0K	$430.0K
YoY Change	46.03%	28.89%	22.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.5M
YoY Change
Common Stock	$149.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.86M	$9.679M	$2.861M
YoY Change
Total Liabilities & Shareholders Equity	$25.70M	$10.26M	$3.290M
YoY Change	150.53%	101.18%	459.52%

Cashflow Statement

Concept	2018 Q2	2017 Q2	2017 Q1
OPERATING ACTIVITIES
Net Income	-$2.587M	-$1.598M	-$806.0K
YoY Change	61.89%	120.72%	91.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.570M	-$688.0K	-$675.0K
YoY Change	128.2%	46.38%	35.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities			$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$491.0K	$7.669M	$0.00
YoY Change	-93.6%	53.07%	-100.0%
NET CHANGE
Cash From Operating Activities	-$1.570M	-$688.0K	-$675.0K
Cash From Investing Activities			0.000
Cash From Financing Activities	$491.0K	$7.669M	$0.00
Net Change In Cash	-$1.079M	$6.981M	-$675.0K
YoY Change	-115.46%	53.77%	68.75%
FREE CASH FLOW
Cash From Operating Activities	-$1.570M	-$688.0K	-$675.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period. Actual results could differ from those estimates.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="white-space: pre-wrap; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company’s financial position at June 30, 2018 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended June 30, 2018 included estimates necessary to value grants of stock option to contractors, employees and various contractors, disclosed in Note 5.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	558000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-2587000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1598000	USD
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18411000	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18794000	shares
	dei	Document Type DocumentType	10-Q
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	798000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	333000	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2018Q2	us-gaap	Revenues Revenues	0	USD
CY2017Q2	us-gaap	Revenues Revenues	0	USD
CY2018Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18794000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18411000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-2404000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1487000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25640000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28260000	USD
CY2017Q4	fencf	Stock Options Issuance StockOptionsIssuance	19000	shares
CY2018Q1	fencf	Stock Options Issuance StockOptionsIssuance	0	shares
CY2018Q2	fencf	Stock Options Issuance Exercised StockOptionsIssuanceExercised	0	shares
	fencf	Stock Options Issuance Exercised StockOptionsIssuanceExercised	-19000	shares
CY2018Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	60000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	128000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2969000	USD
	dei	Trading Symbol TradingSymbol	FENCF
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	167000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1692000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1867000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1146000	USD
	dei	Amendment Flag AmendmentFlag	false
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1020000	shares
CY2018Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2017Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-120000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	167000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-157000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	197000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	342000	USD
CY2018Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	83000	USD
CY2017Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	286000	USD
CY2018Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.50
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2665000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1479000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4456000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2250000	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	13000	USD
	fencf	Stock Options Issuance Forfeited StockOptionsIssuanceForfeited	0	shares
CY2018Q2	fencf	Stock Options Issuance Forfeited StockOptionsIssuanceForfeited	0	shares
CY2018Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1290000	USD
CY2017Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	747000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1578000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	844000	USD
CY2018Q2	fencf	Stock Options Issuance Expired StockOptionsIssuanceExpired	0	shares
	fencf	Stock Options Issuance Expired StockOptionsIssuanceExpired	0	shares
CY2018Q2	us-gaap	Assets Assets	25704000	USD
CY2017Q4	us-gaap	Assets Assets	28401000	USD
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1207000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	461000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1381000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	502000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2018Q2	us-gaap	Cash Cash	6032000	CAD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-157000	USD
CY2017Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-120000	USD
CY2018Q2	fencf	Stock Options Issuance StockOptionsIssuance	0	shares
CY2017Q4	fencf	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice	1.71
CY2018Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	25640000	USD
CY2017Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	28260000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	USD
	dei	Entity Registrant Name EntityRegistrantName	FENNEC PHARMACEUTICALS INC.
CY2018Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	25640000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-68000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-22000	USD
CY2018Q2	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-47000	USD
CY2017Q2	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-11000	USD
CY2018Q2	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-6000	USD
CY2017Q2	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-9000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001211583
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	132000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	8000	USD
CY2018Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	73000	USD
CY2017Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	5000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	709000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	855000	USD
CY2017Q4	us-gaap	Cash Cash	255000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.71
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	138000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	622000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18585000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14192000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18508000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13917000	shares
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	78000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-119000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	301000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-154000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-146000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	52000	USD
CY2018Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-324000	USD
CY2017Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	71000	USD
CY2018Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2000	USD
CY2017Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-38000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-484000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-31000	USD
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Net Income Loss NetIncomeLoss	-4155000	USD
CY2018Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	167000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2018Q2	fencf	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice	0
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	847000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1644000	USD
CY2018Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3297000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1363000	USD
CY2018Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1570000	USD
CY2017Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-688000	USD
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18933242	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	26757000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18508000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13917000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18585000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14192000	shares
CY2018Q2	us-gaap	Liabilities Liabilities	847000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	1644000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18585000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14192000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18508000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13917000	shares
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1	USD
CY2018Q2	fencf	Proceeds From Short Swing Profit Judgment Offset With Settlement Expense ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense	18000	USD
CY2017Q2	fencf	Proceeds From Short Swing Profit Judgment Offset With Settlement Expense ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense	0	USD
	fencf	Proceeds From Short Swing Profit Judgment Offset With Settlement Expense ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense	18000	USD
	fencf	Proceeds From Short Swing Profit Judgment Offset With Settlement Expense ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense	0	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	104010000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	103045000	USD
CY2018Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	473000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	98000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	659000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	98000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2620000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6306000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1079000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6981000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	45127000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	43837000	USD
CY2018Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125523000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121368000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26719000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3251000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3926000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10232000	USD
CY2018Q1	fencf	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	150000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1243000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1243000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	24857000	USD
CY2018Q2	fencf	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	438000	shares
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-1568000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25704000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28401000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	25663000	USD
	fencf	Percentage Of Common Shares Outstanding PercentageOfCommonSharesOutstanding	0.25	pure
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	95000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2018Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2017Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7571000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7571000	USD
CY2018Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	491000	USD
CY2017Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7669000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	677000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7669000	USD
	fencf	Gross Proceeds From Short Swing Profit Judgment Offset With Settlement Expense GrossProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense	25000	USD
	fencf	Payments For Legal Legal Fees And Taxes PaymentsForLegalLegalFeesAndTaxes	7000	USD

Files In Submission

Name	View Source	Status
0001144204-18-043914-index-headers.html	Edgar Link	pending
0001144204-18-043914-index.html	Edgar Link	pending
0001144204-18-043914.txt	Edgar Link	pending
0001144204-18-043914-xbrl.zip	Edgar Link	pending
fencf-20180630.xml	Edgar Link	completed
fencf-20180630.xsd	Edgar Link	pending
fencf-20180630_cal.xml	Edgar Link	unprocessable
fencf-20180630_def.xml	Edgar Link	unprocessable
fencf-20180630_lab.xml	Edgar Link	unprocessable
fencf-20180630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv500190_10q.htm	Edgar Link	pending
tv500190_ex31-1.htm	Edgar Link	pending
tv500190_ex31-2.htm	Edgar Link	pending
tv500190_ex32-1.htm	Edgar Link	pending
tv500190_ex99-1.htm	Edgar Link	pending
tv500190_img01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FENC
FENNEC PHARMACEUTICALS INC. Stock $fenc

2018 Q2 Form 10-Q Financial Statement

#000114420418043914 Filed on August 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FENC FENNEC PHARMACEUTICALS INC. Stock $fenc

2018 Q2 Form 10-Q Financial Statement

#000114420418043914 Filed on August 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FENC
FENNEC PHARMACEUTICALS INC. Stock $fenc